Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.
Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaFebruary 15, 2017
In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.
Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.
Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseFebruary 09, 2017
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
Research from St Jude Children's Research Hospital reveals that acute megakaryoblastic leukemia can be divided into several subgroups with varying prognoses, particularly for children without Down syndrome.
Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.
Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.
I was surprised to see an order for arsenic recently. What is this being used for?
Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.
Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.
Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.
In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.
Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.
What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.
Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.
A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.
In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.
Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.
This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.
Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With CancerOctober 11, 2016
Children with cancer are at risk for developing behavioral problems after diagnosis.
This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.
Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.
Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in SpainSeptember 29, 2016
[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.
Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.
The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).
Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
- Single Chemotherapy Dose Informs Treatment Strategy for Advanced Laryngeal Cancer
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|